Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Immunogenicity of Concomitant Use of V260 and INFANRIX Hexa in Healthy Infants

Trial Profile

Safety and Immunogenicity of Concomitant Use of V260 and INFANRIX Hexa in Healthy Infants

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rotavirus W179-9 vaccine (Primary) ; Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa)
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Rotavirus infections; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Merck & Co

Most Recent Events

  • 01 Mar 2009 Results published in The Pediatric Infectious Disease Journal.
  • 18 Feb 2009 Actual patient number changed from 522 to 403 as reported by ClinicalTrials.gov.
  • 01 Oct 2008 Actual study completion date (June 2007 ) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top